Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.16-.25
$1.7M OFFERING @ .20
https://dilutiontracker.com/app/search/SNOA
SNOA: Hey, Cpt. T-N!!! (I indeed DID get your PM, but --- since I no longer have a subscription to that --- I can only reply to you right here. In any event, THANKS Bro for your heads-up!!)
And let's get this Big Dog FLYIN'!!!!
There is no other symbol. The other one is s private company.
$SNOA being confused with a different Sonoma regarding $REGN deal
— t.k. (@tcarm1) March 28, 2023
The other is private company partnering with REGN
WHATS THE OTHER SYMBOL?
people chased off news from the WRONG TICKER...lol
Sonoma Pharmaceuticals managed to land one serious new customer: the United States government. Sonoma’s Microcyn Rx line of products now have a DAPA, or a Distribution and Pricing Agreement. This opens up their use for the Defense Logistics Agency. This also gives Sonoma’s partner, EMC Pharma, the ability to offer Microcyn Rx products to its own customers in the U.S. government. Half of EMC Pharma’s customer base is U.S. government entities. That, in turn, likely means a nice shot in the profits for Sonoma’s partner firm.
2.68 finally broke $2.44 without meeeeeeeeee
#ARRRRRRRRG
after taking it down to 1.88
im out with profits on the fail to break new ni
Good Morning $SNOA
$SNOA watch for 2.44 break tried 2x already
$2.10 Ran to quick for me might have to pass unless it pulls back some 2.2 million float could do more wonders.
Good luck
Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States
Download as PDFOctober 27, 2022
BOULDER, CO / ACCESSWIRE / October 27, 2022 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care and dermatological conditions, today announced that it has launched Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn® Advanced Skin Repair Cooling Mist direct to consumers for over-the-counter use in the United States.
Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel is a new direct to consumer version of a product previously only available by prescription. Reliefacyn alleviates symptoms such as red bumps, itchy, painful and scaly rashes, shallow skin fissures and peeling, and effectively manages symptoms of eczema/atopic dermatitis. Reliefacyn supports the three phases of healing (inflammation, proliferation and remodeling), and the gel adheres quickly to the skin, making it easy to apply without dripping or running. Reliefacyn is antipruritic, anti-inflammatory, and anti-allergic.
Rejuvacyn® Advanced Skin Repair Cooling Mist is intended for over-the-counter management of minor skin irritations following cosmetic procedures as well as daily skin health and hydration. Formulated to enhance the body's natural healing process, Rejuvacyn aids in recovery following common procedures performed at dermatologists' offices and medical spas such as microdermabrasion, laser treatments, injections, facials, and chemical peels. Rejuvacyn is safe to use around the nose, mouth, and eyes, with a cool mist application that soothes the skin. Rejuvacyn® Advanced Skin Repair Cooling Mist has also been certified as a Natural Personal Care Product by the Natural Products Association.
"We are excited to expand our line of dermatology products to create a portfolio of consumer-focused products that provide healing and relief for common conditions and procedures. We've also formulated Rejuvacyn as an all-natural product for consumers who want to avoid potentially harmful additives in their healthcare regime. Our products will be immediately available through our website, and through third-party distributors," said Amy Trombly, CEO of Sonoma Pharmaceuticals.
For more information about these products, visit https://sonomapharma.com/dermatology-new. You can order Reliefacyn or Rejuvacyn on our website at https://otc.sonomapharma.com or by contacting our customer service department at 720-452-9690 or customerservice@sonomapharma.com.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, and dermatological conditions. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company's products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within
been a long time since i visited this board. but i'm still accumulating SNOA!!! hoping some news comes to do what it did last August !????????????????
So,so news. No $ contracts announced. News catalyst for day trade.
does SNOA ran more on this hand sanitizer news, hold or fall back?
$SNOA news is nothing special but the float already traded in premarket. Could be a serious squeeze here
— M K (@pennystockpickz) October 15, 2021
I noticed your first on the scene for a lot of these runners. Congrats !
Sonoma Pharma, MicroSafe Report Nanocyn Disinfectant, Sanitzer Has Been Approved By Australia Therapeutic Goods Admin.
7:04 am ET October 15, 2021 (Benzinga) Print
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma’s patented Microcyn® Technology.
After original approval by the TGA and entry into The Australian Register Of Therapeutic Goods for use against SARS-CoV-2 (COVID 19) in mid-2020, the TGA has now approved extended claims for the hard-surface disinfectant Nanocyn® with a 15 second kill time against common viruses, including SARS-CoV-2, Norovirus (Gastro), and influenza, and a 30-second kill contact time against common bacteria, such as Staphylococcus aureus (MRSA), E. coli, Pseudomonas aeruginosa, fungi and mold - including Candida Albicans.
“Nanocyn® is a game-changer for any hospital, aged care or health care facility, transportation-provider, business, school, tourism or hospitality venue wanting to ensure their premises are COVID-safe, not just from a pandemic point of view, but also the comfort that comes with using a non-toxic disinfectant that does not leave any harmful residues behind,” said MicroSafe Group CEO Safa Qadumi.
In addition, Nanocyn® had been previously certified by major aviation manufacturers. The product can disinfect aircraft without damaging sensitive materials. It is also the only TGA registered hospital grade disinfectant of its kind to be certified by Good Environmental Choice Australia (GECA).
Bruce Thornton, Chief Operating Officer of Sonoma Pharmaceuticals stated, “We could not be more excited about making our safe and effective Microcyn® Technology available to valued partners such as MicroSafe. We are continuously seeking to add to our network of international distributors to increase the reach of Sonoma products worldwide.”
can we please get back to premarket levels
Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has announced the OTC consumer launch of Regenacyn Advanced Scar Gel and Ocucyn Eyelid & Eyelash Cleanser on Amazon.com and MucoClyns on Amazon sites in Europe.
All three products are based on Sonoma's Microcyn technology and are immediately available for customer orders.
The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel.
Regenacyn Advanced Scar Gel is used to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation.
Ocucyn Eyelid & Eyelash Cleanser, designed for everyday use, is a safe, gentle & effective solution for eyelid & eyelash hygiene.
MucoClyns is a personal decontamination solution for the face and skin. It can be used on mucous membranes, cuts, abrasions, burns, and body surfaces to clean and treat immediately after unexpected exposure to infection risk.
Also Read: Sonoma Stock Doubles On Launch Of Two Dental Products.
Price Action: SNOA stock is up 70.30% at $9.11 during the premarket session on the last check Tuesday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
9.30'S
snoa
Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe
7:00 am ET September 28, 2021 (BusinessWire) Print
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter ("OTC") consumer launch of Regenacyn(R) Advanced Scar Gel and Ocucyn(R) Eyelid & Eyelash Cleanser on Amazon.com, and MucoClyns(TM) on Amazon sites in Europe. All three products are based on Sonoma's patented Microcyn(R) technology and are immediately available for customer orders.
Sonoma is pleased to offer its superior, safe and effective hypochlorous acid products directly to consumers. For years, Sonoma has offered its products as prescription or office dispense products available only from physicians. The OTC launch creates an additional line of Sonoma products marketed directly to consumers and provides a direct channel that makes its proven Microcyn(R) technology widely available for all.
Regenacyn Advanced Scar Gel is clinically proven to improve the overall appearance of scars while reducing pain, itch, redness and inflammation. Regenacyn Advanced Scar Gel protects and moisturizes wound and scar sites to promote lighter, flatter and less prominent scarring. Regenacyn Advanced Scar Gel is non-toxic, non-irritating and non-sensitizing.
Ocucyn Eyelid & Eyelash Cleanser, designed for everyday use, is a safe, gentle & effective solution for good eyelid & eyelash hygiene. Ocucyn Eyelid & Eyelash Cleanser helps clean dirty and crusty irritated eyelids. Ocucyn Eyelid & Eyelash Cleanser is steroid free, non-irritating, non-cytotoxic, non-sensitizing and requires no special handling.
MucoClyns is a personal decontamination solution for the face and skin. MucoClyns is safe to use on mucous membranes, cuts, abrasions, burns and body surfaces to clean and treat immediately after unexpected exposure to infection risk. MucoClyns is biocompatible for its indicated use and safe and non-irritating to human skin.
Regenacyn(R) Advanced Scar Gel is available for purchase here and Ocucyn(R) Eyelid & Eyelash Cleanser is available for purchase here. For more information, please also visit Sonoma's U.S. website.
MucoClyns(TM) is available at Amazon UK, Germany, France, Italy, and Spain. For more information please also visit the Sonoma Europe website.
Amy Trombly, Chief Executive Officer of Sonoma Pharmaceuticals stated, "we could not be more excited about making our safe and effective products available directly to consumers through Amazon. We look forward to offering our clinically proven and patented Microcyn(R) Technology to a wider range of patients for advanced scar management, eyelid & eyelash hygiene and personal protection spray for the face and skin."
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, disinfectant use and dermatological conditions. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company's products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals(TM), Microcyn(R), Regenacyn(R), MucoClyns(TM), and Ocucyn(R) are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005356/en/
SOURCE: Sonoma Pharmaceuticals, Inc.
SNOA is a great $$$$$ opportunity.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
138
|
Created
|
08/14/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |